TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8836336

Group type: EXPERIMENTAL
Intervention: Mizolastine (10 mg once daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 1428312

Group type: EXPERIMENTAL
Intervention: Diclofenac (3 x 50 mg for 6 weeks)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 158
Study: 6239398

Group type: EXPERIMENTAL
Intervention: Bypass procedures
Number of subjects: 201

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 201
Study: 3553279

Group type: EXPERIMENTAL
Intervention: L-649,923
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29448136

Group type: EXPERIMENTAL
Intervention: DBT + DBT PE
Number of subjects: 26

Group type: COMPARATOR
Intervention: DBT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 27721995

Group type: EXPERIMENTAL
Intervention: Sensory Enrichment Therapy
Number of subjects: 1002
Study: 24191870

Group type: EXPERIMENTAL
Intervention: Fuji I, glass ionomer (GI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rely X Unicem, self-adhesive cement (SA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Adhesor, zinc phosphate cement (ZPh)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Panavia F 2.0, resin cement
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fuji Plus, resin-modified glass ionomer (RMGI)
Number of subjects: 35
Study: 22108523

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 338
Study: 20016012

Group type: EXPERIMENTAL
Intervention: High-energy-density (HED) snack food (60g daily for 14 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low-energy-density (LED) snack food (60g daily for 14 days)
Number of subjects: 53
Study: 18089623

Group type: EXPERIMENTAL
Intervention: 200 mg of sulodexide
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 400 mg of sulodexide
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 17108871

Group type: EXPERIMENTAL
Intervention: Various medical strategies for weight loss (dietary intervention, physical activity, behavior modification, pharmacotherapy, surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 14604717

Group type: EXPERIMENTAL
Intervention: 10 mg oral clorazepate dipotassium
Number of subjects: 97

Group type: COMPARATOR
Intervention: 1 mg intravenous midazolam
Number of subjects: 97
Study: 10924737

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 8810584

Group type: EXPERIMENTAL
Intervention: Small stimulus (S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large stimulus (L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SLLL sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LSSS sequences
Number of subjects: 0
Study: 1430679

Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy (rt-PA and urokinase)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Urokinase monotherapy
Number of subjects: 287

Group type: COMPARATOR
Intervention: rt-PA monotherapy
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy
Number of subjects: 287
Study: 6374780

Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg daily for five days a week)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 75
Study: 30394988

Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 321

Group type: COMPARATOR
Intervention: Radical resection
Number of subjects: 321
Study: 30187524

Group type: EXPERIMENTAL
Intervention: 5% dextrose (D5W) injection, 5ml
Number of subjects: 54

Group type: COMPARATOR
Intervention: Corticosteroid (triamcinolone acetonide) injection, 3ml mixed with 2ml normal saline
Number of subjects: 54
Study: 27927219

Group type: EXPERIMENTAL
Intervention: Reference to an earlier systematic review with additional randomised trials
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Reference to an earlier systematic review without additional trials
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Reference to randomised trials in isolation
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Explicit justification for the proposed randomised trial on the basis of being the first to address the research question
Number of subjects: 101

Group type: COMPARATOR
Intervention: A randomised controlled trial was not cited
Number of subjects: 101

Group type: COMPARATOR
Intervention: A systematic review was cited but did not inform trial design
Number of subjects: 101
Study: 24015666

Group type: EXPERIMENTAL
Intervention: Bucketball (3 vs. 3 and 6 vs. 6)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bucketball (6 vs. 6)
Number of subjects: 10
Study: 22899707

Group type: EXPERIMENTAL
Intervention: community-coordinated, victim-focused outreach program
Number of subjects: 236
Study: 20819631

Group type: EXPERIMENTAL
Intervention: 0.05 microg x kg(‐1) x h(‐1) naloxone (group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.1 microg x kg(‐1) x h(‐1) naloxone (group III)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.2 microg x kg(‐1) x h(‐1) naloxone (group IV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no naloxone, group I)
Number of subjects: 80
Study: 17972359

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus selegiline 10 mg/day (5 mg bid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 40
Study: 15948609

Group type: EXPERIMENTAL
Intervention: Rapid presentation (150 ms/item)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow presentation (500 ms/item)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both rapid and slow presentations
Number of subjects: 0
Study: 12955641

Group type: EXPERIMENTAL
Intervention: Single-dose liposomal amphotericin B (L-AmB) 7.5 mg/kg
Number of subjects: 203
Study: 10735688

Group type: EXPERIMENTAL
Intervention: Continuous infusion of mannitol, furosemide, and dopamine (group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intermittent doses of diuretics (furosemide, bumetadine, and ethracrynic acid) and fluids (group A)
Number of subjects: 100
Study: 8716750

Group type: EXPERIMENTAL
Intervention: Continuous infusion of morphine (CIM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent intramuscular injection of pethidine (IMP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CIM and IMP
Number of subjects: 40
Study: 1350804

Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9) with condoms
Number of subjects: 343

Group type: COMPARATOR
Intervention: Condoms only (placebo)
Number of subjects: 343
Study: 4006549

Group type: EXPERIMENTAL
Intervention: Naloxone pretreatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Short-term intravenous naloxone administration
Number of subjects: 6
Study: 30702403

Group type: EXPERIMENTAL
Intervention: Bleaching treatment with room temperature storage (21.04°C±3.13°C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bleaching treatment with refrigerated storage (5°C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subjective evaluation using Vita Classic
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subjective evaluation using Vita Bleachedguide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Objective evaluation using Vita Easyshade spectrophotometer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Consistency test of bleaching gels
Number of subjects: 30
Study: 28034564

Group type: EXPERIMENTAL
Intervention: 200 ml black tea
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27535435

Group type: EXPERIMENTAL
Intervention: Autologous Chondrocyte Implantation (ACI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Surviving patients in ACI group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surviving patients in microfracture group
Number of subjects: 80
Study: 24065124

Group type: EXPERIMENTAL
Intervention: PEG‐IFN/RBV combination therapy
Number of subjects: 326
Study: 21972425

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21190455

Group type: EXPERIMENTAL
Intervention: Collaborative care management by a medically supervised nurse
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 18715200

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 476

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 476
Study: 15704420

Group type: EXPERIMENTAL
Intervention: Dichotic pitch stimulus
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Active response to stimuli
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ignored random stimuli while watching silent cartoons
Number of subjects: 11
Study: 12552319

Group type: EXPERIMENTAL
Intervention: Isotonic % 0.9 saline (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5% glucose solutions (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 80
Study: 10601539

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (20 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 60
Study: 8835632

Group type: EXPERIMENTAL
Intervention: Inhalational anaesthesia (isoflurane)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neuroleptoanalgesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 30
Study: 2206833

Group type: EXPERIMENTAL
Intervention: Michel clips
Number of subjects: 50

Group type: COMPARATOR
Intervention: Interrupted monofilament nylon sutures
Number of subjects: 50
Study: 6107100

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 0
Study: 31113476

Group type: EXPERIMENTAL
Intervention: Re‐Join®
Number of subjects: 53

Group type: COMPARATOR
Intervention: HA (Hyaluronic Acid)
Number of subjects: 53
Study: 28720029

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 0
Study: 25668399

Group type: EXPERIMENTAL
Intervention: Supervised progressive impact exercise program three times a week for 12 months (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonintervention control group (n = 40)
Number of subjects: 80
Study: 24083027

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for eight weeks)
Number of subjects: 20
Study: 21713577

Group type: EXPERIMENTAL
Intervention: Anterior hiatal repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: Posterior hiatal repair
Number of subjects: 102
Study: 19878027

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No laser irradiation (control group)
Number of subjects: 21
Study: 16968580

Group type: EXPERIMENTAL
Intervention: Omalizumab add-on therapy
Number of subjects: 419

Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 419
Study: 12534583

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Aspirin 500 mg
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study: 10772374

Group type: EXPERIMENTAL
Intervention: Intervention by ambulatory care clinical pharmacists
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: In-person contacts
Number of subjects: 523
Study: 9037323

Group type: EXPERIMENTAL
Intervention: Phenylephrine (1 microgram/kg) infusion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1 microgram/kg) infusion
Number of subjects: 16
Study: 8584604

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (5% sodium chloride at 0.06 ml/kg/min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo infusion (0.9% sodium chloride at 0.06 ml/kg/min)
Number of subjects: 21
Study: 2670535

Group type: EXPERIMENTAL
Intervention: ACC‐9653 (PHT prodrug) administered intravenously (i.v.)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ACC‐9653 (PHT prodrug) administered intramuscularly (i.m.)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Comparison of area under curve (AUC) ratio of PHT after i.m. and i.v. ACC‐9653
Number of subjects: 43
Study: 324279

Group type: EXPERIMENTAL
Intervention: Amikacin plus penicillin (A+P)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Amikacin plus carbenicillin (A+C)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Synergistic combinations
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Bacteremic patients
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: High bactericidal activity (≥ 1/8)
Number of subjects: 117
Study: 29656669

Group type: EXPERIMENTAL
Intervention: Facilitated tucking position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine position
Number of subjects: 40
Study: 29911793

Group type: EXPERIMENTAL
Intervention: Personal support
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Neighborhood support
Number of subjects: 1000
Study: 25814428

Group type: EXPERIMENTAL
Intervention: Six different moistening solutions (specific solutions not detailed)
Number of subjects: 58
Study: 24372155

Group type: EXPERIMENTAL
Intervention: Fast ice cream consumption (5 min)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Slow ice cream consumption (30 min)
Number of subjects: 3
Study: 21734976

Group type: EXPERIMENTAL
Intervention: EDSC (Excite DSC)/V
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: EDSC-V LC (One Shot)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Variolink II (V)
Number of subjects: 105

Group type: COMPARATOR
Intervention: V light‐cured (LC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Excite LC (ELC)/V
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ELC/V LC
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: ELC‐V LC (One Shot)
Number of subjects: 105
Study: 19221352

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin lispro)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin aspart)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin lispro) in type 2 diabetes
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin analogues (insulin aspart) in type 2 diabetes
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin glargine)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin detemir)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin glargine) in type 2 diabetes
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Long-acting insulin analogues (insulin detemir) in type 2 diabetes
Number of subjects: 117

Group type: COMPARATOR
Intervention: Insulin analogues
Number of subjects: 117
Study: 17319816

Group type: EXPERIMENTAL
Intervention: Retransfusion system (Bellovac, AstraTech AB)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Regular drain (Abdovac, AstraTech AB)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 160
Study: 15378838

Group type: EXPERIMENTAL
Intervention: High doses of plutonium
Number of subjects: 0

Group type: COMPARATOR
Intervention: High doses of gamma rays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High plutonium and high gamma-ray groups
Number of subjects: 0
Study: 12600112

Group type: EXPERIMENTAL
Intervention: Aprotinin (3 x 10^6 added to the priming solution of ECC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amrinone combined with aprotinin (3 x 10^6 aprotinin + bolus of 1 mg/kg amrinone followed by 8 micrograms/(kg.min) maintenance infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (equivalent prime volume without aprotinin)
Number of subjects: 24
Study: 9379354

Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg)
Number of subjects: 0
Study: 1586821

Group type: EXPERIMENTAL
Intervention: Home physiotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Day hospital attendance
Number of subjects: 124
Study: 3099486

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg (30 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg (120 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg (240 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg (480 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Continuation of ISDN 80 mg (480 mg/day) for 4 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 2.6 mg (single dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 6.5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 20 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 5 cm2 patch
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 10 cm2 patch
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin 20 cm2 patch
Number of subjects: 15
Study: 30372511

Group type: EXPERIMENTAL
Intervention: Perceived sleep quality (assessed using the Pittsburgh Sleep Quality Index - PSQI)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Perceived sleep quality
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Depression severity
Number of subjects: 200
Study: 29458406

Group type: EXPERIMENTAL
Intervention: Pyriproxyfen/spinosad combination treatment of permanent water storage containers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26746044

Group type: EXPERIMENTAL
Intervention: IV TXA
Number of subjects: 100
Study: 25358424

Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service (BIS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study: 22664558

Group type: EXPERIMENTAL
Intervention: Spaced-education game (SE game) with 40 validated multiple-choice questions, sent 2 questions every 2 days (Cohort A)
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Spaced-education game (SE game) with 40 validated multiple-choice questions, sent 4 questions every 4 days (Cohort B)
Number of subjects: 1470
Study: 19879596

Group type: EXPERIMENTAL
Intervention: Colesevelam 1.875 g/d
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/d
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 16839823

Group type: EXPERIMENTAL
Intervention: telephone‐based, individualized motivationally‐tailored feedback
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: print‐based, individualized motivationally‐tailored feedback
Number of subjects: 239

Group type: COMPARATOR
Intervention: contact‐control delayed treatment group
Number of subjects: 239
Study: 17012863

Group type: EXPERIMENTAL
Intervention: fowlpox + HIV genes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: fowl pox + HIV genes + interferon gamma
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study: 12066113

Group type: COMPARATOR
Intervention: Paracervical block with no wait (group 1, n = 93)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Paracervical block with 3-5 minute wait (group 2, n = 101)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Fentanyl (used during the procedure)
Number of subjects: 199
Study: 9461356

Group type: EXPERIMENTAL
Intervention: Spina bifida patients
Number of subjects: 148

Group type: COMPARATOR
Intervention: Atopic children
Number of subjects: 148

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Spina bifida patients with latex sensitization
Number of subjects: 148
Study: 8534533

Group type: EXPERIMENTAL
Intervention: 3 L of balanced electrolyte/polyethylene glycol solution (PEG)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Senna laxatives and sodium phosphate enemas
Number of subjects: 216
Study: 2120087

Group type: EXPERIMENTAL
Intervention: Ovarian cyst aspiration in group A
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-aspirated ovarian cysts in group A
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Ovarian cyst aspiration in group B
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-aspirated ovarian cysts in group B
Number of subjects: 37
Study: 7004480

Group type: EXPERIMENTAL
Intervention: Chymoral (exact dosage and duration not specified)
Number of subjects: 102
Study: 31908066

Group type: EXPERIMENTAL
Intervention: SR-dexamphetamine (2 x 30 mg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 30422953

Group type: EXPERIMENTAL
Intervention: Immunosuppressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 29211123

Group type: EXPERIMENTAL
Intervention: Morse Taper (MT) implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: External Hexagon (EH) implants
Number of subjects: 40
Study: 24936090

Group type: EXPERIMENTAL
Intervention: Brief advice consisting of feedback on alcohol and health, written information, and an offer of an appointment with an Alcohol Health Worker
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control treatment consisting of a leaflet on health and lifestyle
Number of subjects: 802
Study: 23376474

Group type: EXPERIMENTAL
Intervention: Point-light walker (PLW) stimulus
Number of subjects: 24
Study: 21545399

Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg twice daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 131